Quality assessment for therapeutic drug monitoring in AIDS clinical trials group (ACTG 5146): A multicenter clinical trial

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 458-466

  Difrancesco, Robin ^a   Rosenkranz, Susan ^b   Mukherjee, A Lisa ^b   Demeter, Lisa M ^c   Jiang, Hongyu ^b   Dicenzo, Robert ^a   Dykes, Carrie ^c   Rinehart, Alex ^d   Albrecht, Mary ^e   Morse, Gene D ^a  

^a SUNYat Buffalo ^*  (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Infectious Diseases Divisio   (United States)

^d Tibotec Therapeutics   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

AIDS Clinical Trials Group; HIV 1 protease inhibitors (PIs); optimize drug exposure; protocol 5146; therapeutic drug monitoring

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; MULTICENTER STUDY; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD; CALIBRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; LABORATORY; LABORATORY DIAGNOSIS; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIBRATION; DRUG MONITORING; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LABORATORIES; QUALITY CONTROL; SPECIMEN HANDLING; TREATMENT OUTCOME;

EID: 77955171884     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181e4427a     Document Type: Article

References (30)

1. Hammer SM, Eron, JJ Jr, Reiss P, et al. Treatment for adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
2. European AIDS Clinical Society (EACS) HIV Guidelines. Available at: www.aidsportal.org. Accessed May 21, 2009.
3. Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral- experienced, HIV-1-infected patients. AIDS. 2009;23:357-368.
4. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50:3801-3808.
5. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 2000;14:1333-1339.
6. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Anti-microb Agents Chemother. 2002;46:3907-3916.
7. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350-359.
8. Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47:594-600.
9. Casado JL, Moreno A, Sabido R, et al. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS. 2003;17:262-264.
10. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2004;75:310-323.
11. De Luca A, Baldini F, Cingolani A, et al. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr. 2004;35: 359-366.
12. Gonzalez de Requena D, Gallego O, Valer L, et al. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses. 2004;20:275-278.
13. Castagna A, Gianotti N, Galli L, et al. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antivir Ther. 2004;9:537-543.
14. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5:201-205.
15. Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2004;48:4687-4692.
16. Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2005;49:1720-1726.
17. Winston A, Hales G, Amin J, et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS. 2005;19:1393-1399.
18. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5:352-359.
19. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551-560
20. Available at: www.cms.hhs.gov/clia/09-clia-regulations-and-federal- register-documents.asp, Accessed November 2009.
21. Keil K, Difrancesco R, Morse GD. Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array. Ther Drug Monit. 2006;28:512-516.
22. Keil K, Hochreitter J, DiFrancesco R, et al. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Ther Drug Monit. 2007;29:103-109.
23. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AACTG proficiency testing program for pharmacology laboratories. Antimicrobial Agent Chemother. 2004;48:824-831.
24. Holland DT, DiFrancesco R, Connor JD, et al. ACTG proficiency testing for pediatric and adult pharmacology support laboratories. Ther Drug Monit. 2006;28:367-374.
25. Droste JAH, Aarnoutse RE, Koopmans PP, et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32:287-291.
26. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW, et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrobial Agent Chemother. 2002;46:884-886.
27. DiFrancesco R, Rosenkranz SL, Craft J, et al. Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints. HIV Clin Trials. 2006;7:203-209.
28. Thrasher AD, Earp JA, Golin CE, et al. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84-93.
29. Clevenbergh P, Garraffo R, Durant J, et al. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002;16:2311-2315.
30. Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46:433-442.